UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 1, 2009

NUVILEX, INC.

(Exact name of registrant as specified in its charter)

333-68008	62-1772151
(Commission File Number)	(IRS Employer Identification No.)
	08034
fices)	(Zip Code)
uding area code (856) 354-0707	
27/4	
	ce last report.)
der any of the following provisi	
ant to Rule 423 under the Secur	titles Act (17 CFR 230.423)
□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)	
cations pursuant to Rule 14d-2	2(b) under the Exchange Act (17
cations pursuant to Rule 13e-4	(c) under the Exchange Act (17
	(Commission File Number) fices) uding area code (856) 354-0707 N/A or former address, if changed sin if the Form 8-K filing is inten der any of the following provisi ant to Rule 425 under the Securi Rule 14a-12 under the Exchange cations pursuant to Rule 14d-2

Section 3 - Securities and Trading Markets

Item 3.02 Unregistered Sales of Equity Securities.

Mr. Robert S. Trump, a successful entrepreneur and an accredited investor based in New York, has acquired five million five hundred fifty-five thousand five hundred and fifty (5,555,555) restricted shares of Nuvilex, Inc. Common Stock for a cash investment made to the Company in the amount of two-hundred and fifty thousand dollars (\$250,000). The restricted (Securities Act Rule 144) Common Stock purchase was made at \$0.045 per share. Mr. Trump first became familiar with the Company as a consumer of the Company's retail products, CinnergenTM and CinnecholTM. Mr. Trump's personal results from the use of these products were excellent and as a result Mr. Trump made this investment in support of the Company's growth strategy and business plans.

The Company believes the issuance of the shares is exempt from the registration and prospectus delivery requirement of the Securities Act of 1933 by virtue of Section 4(2). The shares were issued directly by the Company and did not involve a public offering or general solicitation. The recipient of the shares was afforded an opportunity for effective access to files and records of the Company that contained the relevant information needed to make his investment decision, including the Company's financial statements and 34 Act reports. The Company reasonably believed that the recipient had such knowledge and experience in its financial and business matters that he was capable of evaluating the merits and risks of his investment.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NUVILEX, INC. (Registrant)

Date: October 1, 2009

/s/ Martin Schmieg
Martin Schmieg
Chief Executive Officer